Assembly Biosciences
Open
$23.35
Prev. Close
$23.35
High
$23.35
Low
$23.24
Market Snapshot
$370.08M
-58.0
-6.72
73
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Recently from Cashu
Assembly Biosciences' Promising Advances in HSV and Liver Disease Treatments with Gilead Partnership
Assembly Biosciences is making notable advancements in its research efforts targeting the herpes simplex virus (HSV), a development that holds potential for significant impact in the biotech landscape…
Assembly Biosciences Targets Herpes and Liver Diseases in Promising 2024 Research Developments
Assembly Biosciences is making significant advancements in its research targeting herpes simplex virus (HSV), showcasing a commitment to addressing viral diseases. During a recent Jefferies biotech ev…
U.S. Intervention Highlights Iran's Supreme Leadership Transition and Its Geopolitical Implications
Titular Transition: A Turning Point for Iran's Supreme Leadership As the Assembly of Experts in Iran prepares to confirm a new supreme leader, the political landscape in the region is underscored by g…
Impending Supreme Leader Selection in Iran Raises Stakes for U.S.-Iran Relations
Impending Leadership Transition at the Heart of Iran's Governance The Assembly of Experts in Iran is poised to confirm a new supreme leader, an event that carries significant ramifications not only fo…